Status:
TERMINATED
Study of LAU-7b for the Treatment of Coronavirus Disease 2019 (COVID-19) Disease in Adults
Lead Sponsor:
Laurent Pharmaceuticals Inc.
Conditions:
COVID-19 Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
A randomized, double-blind, placebo-controlled Phase 2/3 Study of LAU-7b against confirmed COVID-19 Disease in hospitalized patients at a higher risk of complications.
Detailed Description
RESOLUTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2/3 study of LAU-7b for the treatment of COVID-19 Disease in participants at a higher risk than the general COVID-19 Dis...
Eligibility Criteria
Inclusion
- Participant exhibited symptoms \[Extension Phase 3 study only: (including at least one lower respiratory symptom such as shortness of breath or dyspnea)\] of COVID-19 disease at screening and/or since the start of their hospitalization (may have included treated symptoms)
- Participant was 18 years and older, of either gender
- Participant must have had at least one of the following factors/co-morbidities:
- Controlled or uncontrolled diabetes
- Pre-existing cardiovascular disease, including hypertension
- Pre-existing respiratory disease such as chronic obstructive pulmonary disease(COPD), asthma, emphysema
- Active \[Extension Phase 3 study only: or a former smoker\] with 20 pack-years of smoking history
- Obesity as depicted by BMI ≥30 kg/m2
- Laboratory tests indicative of a higher risk of COVID-19-related complications, such as troponin \>1.5 the upper limit of normal (ULN), \[Extension Phase 3 study only: D-dimer \>3.0 ULN\] and/or C reactive protein (CRP) \>1.5 ULN
- Aged 70 years and older who, based on the judgment of the investigator, was at a higher risk of developing complications
- Participant had a documented positive test for the SARS-CoV-2 virus \[Pilot Phase 2 study only: or was suspected to be positive and with a test result pending\]. \[Extension Phase 3 study only: Co-infection with other viral respiratory infections was allowed and had to be documented in medical history\]
- Participant was under observation by, or admitted to, a controlled facility or hospital \[Extension Phase 3 study only: for no more than 48 hours (72 hours from amendment 3 onwards) before screening, including any prior stay in another hospital\] to receive standard of care (SoC) for COVID-19 disease
- \[Pilot Phase 2 study only: Participant's hs was 3, 4, or 5 on the WHO ordinal scale and not previously a "6"\] \[Extension Phase 3 study only: 3 or 4 on the World Health Organization (WHO) ordinal scale and not previously a "5 or a 6"\]
- If female, participant was either post-menopausal (one year or greater without menses), surgically sterile, or, for female subjects of child-bearing potential who were capable of conception had to be practicing a highly effective method of birth control (acceptable methods included intrauterine device, complete abstinence, spermicide + barrier, male partner surgical sterilization, or hormonal contraception) during the study and through 30 days after the last dose of the study medication. Periodical abstinence was not classified as an effective method of birth control. A pregnancy test had to be negative at the Screening Visit
- Participant had the ability to understand and give informed consent, which could have been verbal with a witness, according to local requirements
- Participant was deemed capable of adequate compliance including attending scheduled visits for the duration of the study
- Participant was able to swallow the study drug capsules
Exclusion
- Pregnancy or breastfeeding
- Health condition deemed to possibly interfere with the study endpoints and/or the safety of the participants. For example, the following conditions were considered contraindicated for participation in the study, but this was not an exhaustive list. In case of doubt, the investigator was to consult with the Sponsor's medical representative:
- Presence of inherited retinitis pigmentosa
- Presence or history of liver failure (Child-Pugh B or C)
- Presence or history of stage 4 severe chronic kidney disease or dialysis requirement
- Febrile neutropenia
- \[Pilot Phase 2 study: Presence of active cancer treated with systemic chemotherapy or radiotherapy\]\[Extension Phase 3 study: Presence of end-stage cancer\]
- Known history of a severe allergy or sensitivity to retinoids, or with known allergies to excipients in the oral capsule formulation used in the study
- Participation in another drug clinical trial within 30 days (or a minimum of 5 t½) prior to screening, except ongoing participation in non-interventional studies
- Calculated creatinine clearance (CrCl), using the Cockroft-Gault equation for example \[Pilot Phase 2 study: \<60 mL/min\] \[Extension Phase 3 study: \<30 mL/min)\]
- Presence of total bilirubin \>1.5 x ULN (in the absence of demonstrated Gilbert's syndrome), alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \>2.5 x ULN
- \[Extension Phase 3 study only: Subject expected to be transferred to ICU or die in the next 24 hours\]
Key Trial Info
Start Date :
August 18 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 30 2024
Estimated Enrollment :
351 Patients enrolled
Trial Details
Trial ID
NCT04417257
Start Date
August 18 2020
End Date
May 30 2024
Last Update
November 13 2025
Active Locations (29)
Enter a location and click search to find clinical trials sorted by distance.
1
Chandler Regional Medical Center / Mercy Gilbert Medical Center
Chandler, Arizona, United States, 85224
2
Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States, 92663
3
University of California Davis Medical Center
Sacramento, California, United States, 95817
4
Nuvance Health - Danbury Hospital
Danbury, Connecticut, United States, 06810